During the last years other chemokines which bind to the CXCR2 receptor have been studied, such as CXCL1, although curiously the systemic administration of the CXCL1 antibody was much less effective in reducing the PCTX-induced peripheral neuropathy than intrathecal administration, possibly indicating different chemokine involvement in the PNS and central nervous system (CNS) (Manjavachi et al., 2019). Here, CXCL1 is linked to peripheral neuropathy.